Allogeneic hematopoietic stem cell transplantation: State of the art and new perspectives

APMIS

Volumn 113, Issue 11-12, 2005, Pages 813-830

  Ringdén, Olle ^a   Le Blanc, Katarina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease; Leukaemia; Mesenchymal stem cells

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 2 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PSORALEN; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; STEROID; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VORICONAZOLE;

ADIPOCYTE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ANTINEOPLASTIC ACTIVITY; APLASTIC ANEMIA; ARTHRALGIA; BACTERIAL INFECTION; BONE CELL; BONE MARROW TOXICITY; BRONCHIOLITIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARTILAGE CELL; CELL DIFFERENTIATION; CELL ISOLATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOPENIA; DRUG BLOOD LEVEL; GINGIVA HYPERPLASIA; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMORRHAGIC CYSTITIS; HIRSUTISM; HLA MATCHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOMODULATION; INFECTION SENSITIVITY; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA RELAPSE; LIVER TOXICITY; LYMPHOCYTE TRANSFER; METASTASIS; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MYCOSIS; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; VEIN OCCLUSION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BLOOD DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY;

GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33645463906     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2005.apm_336.x     Document Type: Review

References (178)

1. Thomas ED, Lochte HL Jr., Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957 257 : 491 6.
2. Dausset J, Brecy H. Identical nature of the leucocyte antigens detectable in monozygotic twins by means of immuno iso-leuco-agglutinins. Nature 1957 180 : 1430.
3. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968 2 : 1366 9.
4. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968 2 : 1364 6.
5. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977 49 : 511 33.
6. Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg HJ, Fefer A, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987 5 : 1340 7.
7. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996 14 : 572 8.
8. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. The European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996 124 : 311 5.
9. Storb R, Thomas ED, Weiden PL, Buckner CD, Clift RA, Fefer A, et al. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood 1976 48 : 817 41.
10. Groth CG, Ringdén O. Transplantation in relation to the treatment of inherited disease. Transplantation 1984 38 : 319 27.
11. Peters C. Hematopoietic cell transplantation for storage diseases. In : Blume KG, Forman SJ, Appelbaum FR editors. Thomas' Hematopoietic Cell Transplantation. Third edition. Oxford : Blackwell Publishing Ltd., 2004 : 1455 70.
12. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sander JE, Martin PJ, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991 51 : 443 7.
13. Hows JM, Bradley BA, Gore S, Downie T, Howard M, Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1993 12 : 371 80.
14. Speiser DE, Tiercy JM, Rufer N, Grundschober C, Gratwohl A, Chapuis B, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996 87 : 4455 62.
15. Ringdén O. Bone marrow transplantation using unrelated donors for hematological malignancies. Med Oncol 1997 14 : 11 22.
16. Ringdén O, Schaffer M, Le Blanc K, Persson U, Hauzenberger D, Abedi MR, et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B and -DRb1 genomically identical volunteers? Biol Blood Marrow Transplant 2004 10 : 128 34.
17. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (G-CSF). Blood 1995 85 : 1666 72.
18. Bensinger W, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996 88 : 2794 800.
19. Ringdén O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 2002 20 : 4655 64.
20. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997 90 : 4705 9.
21. Ringdén O, Remberger M, Runde V, Bornhäuser M, Blau WI, Basara N, et al. Peripheral blood stem cell (PBSC) transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999 94 : 455 64.
22. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringdén O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005 105 : 548 51.
23. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR, Ringdén O, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004 22 : 4872 80.
24. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997 337 : 373 81.
25. Wagner J, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996 88 : 795 802.
26. Ballen KB. New trends in umbilical cord blood transplantation. Blood 2005 105 : 3786 92.
27. Westgren M, Ringdén O. Fetal to fetal transplantation. Acta Obstet Gynecol Scand 1994 73 : 371 2.
28. Storb R, Thomas ED. Allogeneic bone-marrow transplantation. Immunol Rev 1983 71 : 77 102.
29. Santos WG. Workshop Summary: Preparative regimens for allogeneic bone marrow transplantation in leukemia. In : Gale RP editor. Progress in Bone Marrow Transplantation. New York : Alan R. Liss, Inc., 1987 : 113 9.
30. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987 70 : 1382 8.
31. Ringdén O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindeløv L. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia using busulfan compared to total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. The Nordic Bone Marrow Transplantation Group. Blood 1999 93 : 2196 201.
32. Socié G, Clift RA, Blaise D, Devergie A, Ringdén O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001 98 : 3569 74.
33. Hassan M, Ljungman P, Bolme P, Ringdén O, Syruccková Z, Békàssy A, et al. Busulphan bioavailability. Blood 1994 84 : 2144 50.
34. Storb R, Weiden PL, Sullivan KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987 70 : 116 21.
35. Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CJC, Barnes R. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986 1 : 193 200.
36. Ringdén O, Remberger M, Svahn BM, Barkholt L, Aschan J, Mattsson J, et al. Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single-center. Transplantation 2005 in press.
37. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fischer LD, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990 76 : 1867 71.
38. Buckner CD, Clift RA, Appelbaum FR, Storb R, Petersen FB, Sanders JE, et al. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. Bone Marrow Transplant 1991 7 ( Suppl 2 6.
39. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998 91 : 756 63.
40. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringdén O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003 101 : 469 72.
41. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997 89 : 4531 6.
42. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999 94 : 3234 41.
43. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersäll P, Pisa P, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003 31 : 253 61.
44. McSweeney P, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999 5 : 192 203.
45. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001 97 : 3390 400.
46. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003 101 : 1620 9.
47. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringdén O. A comparison of non-myeloablative and reduced intensity conditioning for allogeneic stem cell transplantation. Transplantation 2004 78 : 1014 20.
48. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004 104 : 961 8.
49. Marmont AM, Horowitz MM, Gale RP, Ash RC, van Bekkum DW, Champlin RE, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1990 78 : 2120 30.
50. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Eng J Med 1989 320 : 197 204.
51. Nemunaitis J. The role of hematopoietic growth factor in the treatment of graft failure. Bone Marrow Transplant 1993 12 ( Suppl 3) S50 2.
52. Storb R, Weiden PL. Transfusion problems associated with transplantation. Seminars in Hematology 1981 18 : 163 76.
53. Pihlstedt P, Paulin T, Sundberg B, Nilsson B, Ringdén O. Blood transfusion in marrow graft recipients. Ann Hematol 1992 65 : 65 70.
54. Buckner CD, Clift RA, Sanders JE, Meyers JD, Counts GW, Farewell VT, et al. Protective environment for marrow transplant recipients: a prospective study. Ann Int Med 1978 89 : 893 901.
55. Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A, et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998 21 : 1231 8.
56. Svahn BM, Remberger M, Myrbäck KE, Holmberg K, Eriksson B, Hentschke P, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared to hospital care. Blood 2002 100 : 4317 24.
57. Svahn BM, Ringdén O, Remberger M. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2005 36 : 511 6.
58. Appelbaum F. Allogeneic marrow transplantation and the use of hematopoietic growth factors. Stem Cells 1995 13 : 344 50.
59. Ringdén O, Le Blanc K, Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions and future applications. Exp Hematol 2005 33 : 505 12.
60. Ringdén O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukaemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 2004 22 : 416 23.
61. Hägglund H, Ringdén O, Öman S, Remberger M, Carlens S, Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999 24 : 831 6.
62. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svenberg P, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003 32 : 217 23.
63. Klaesson S, Ringdén O, Ljungman P, Lönnqvist B, Wennberg L. Reduced blood transfusion requirements after allogeneic bone marrow transplantation - results of a randomised, double-blind study with high dose erythropoietin. Bone Marrow Transplant 1994 13 : 397 402.
64. Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970 9 : 240 6.
65. Ringdén O. Cyclosporin in allogeneic bone marrow transplantation. Transplantation 1986 42 : 445 52.
66. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beattly P, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989 73 : 1729 34.
67. Ringdén O, Horowitz MM, Sondel P, Gale RP, Biggs JG, Champlin RE, et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood 1993 81 : 1094 101.
68. Ringdén O, Bäckman L, Lönnqvist B, Heimdahl A, Lindholm A, Bolme P, et al. A randomized trial comparing the use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematologic malignancies. Bone Marrow Transplant 1986 1 : 41 51.
69. Winston DJ, Ho WG, Lin CH, Bartony K, Budinger M, Gale R, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplants. Ann Intern Med 1987 106 : 12 8.
70. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990 323 : 705 12.
71. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Int Med 1988 108 : 806 14.
72. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1990 75 : 555 62.
73. Ringdén O, Kersey JH. Prevention and therapy of graft-versus-host disease. Report from a workshop. Bone Marrow Transplant 1992 10 ( Suppl 1 22 4.
74. Nash R, Pineiro L, Storb R, Deeg HJ, Fitzsimmons WE, Furlong T, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996 88 : 3634 41.
75. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996 87 : 3514 9.
76. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003 102 : 1601 5.
77. Remberger M, Storer B, Ringdén O, Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002 29 : 391 7.
78. Ringdén O, Remberger M, Persson U, Ljungman P, Aldener A, Andström E, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995 15 : 619 25.
79. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001 98 : 2942 7.
80. Remberger M, Svahn BM, Mattsson J, Ringdén O. A dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004 78 : 122 7.
81. Ringdén O. Management of graft-versus-host disease. Eur J Haematol 1993 51 : 1 12.
82. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringdén O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001 15 : 147 53.
83. van Bekkum DW edito. Graft-versus-host disease. New York : Marcel Dekker, Inc., 1985.
84. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 1985 88 : 215 38.
85. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In : Ferrara JLM, Deeg HJ, Burakoff S editors. Graft vs Host Disease. Second Edition. New York : Marcel Dekker, Inc., 1996 : 525 59.
86. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transpl 1999 5 : 347 56.
87. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981 57 : 267 76.
88. Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K, et al. Chronic cutaneous graft-versus-host disease in man. Am J Path 1978 91 : 545 70.
89. Lee SJ, Klein JP, Barrett AJ, Ringdén O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002 100 : 406 14.
90. Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, et al. Risk-factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998 22 : 755 61.
91. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Int Med 1983 98 : 461 6.
92. Ringdén O, Paulin T, Lönnqvist B, Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease. Exp Hematol 1985 13 : 1062 7.
93. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Transplantation 2004 104 : 2603 6.
94. Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In : Rubin RH, Young LS editors. Clinical approach to infection in the compromised host. New York : Plenum Publishing Corp., 1988 : 525 56.
95. Sparrelid E, Hägglund H, Remberger M, Ljungman P, Malmborg AS, Winiarski J, et al. Risk factors for septicaemia during aplastic period after allogeneic bone marrow transplantation. Transplant Proc 1995 27 : 3530.
96. Tollemar J, Ringdén O, Boström L, Nilsson B, Sundberg B. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989 4 : 635 41.
97. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990 17 ( Suppl 6 10 3.
98. Tollemar J, Ringdén O, Tydén G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin Transplant 1990 4 : 167 75.
99. Ringdén O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse ER, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991 28 ( Suppl B 73 82.
100. Ekelöf Andström E, Ringdén O, Remberger M, Svahn BM, Tollemar J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996 39 : 185 93.
101. Buchman TH, Rossier M, Merz W, Charache P. Detection of surgical pathogens by in vitro DNA amplification. Part I. Rapid identification of Candida albicans by in vitro amplification of a fungus-specific gene. Surgery 1990 108 : 338 47.
102. Hebart H, Loffler J, Meisner C, Serey F, Schmidt D, Bohme A, et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000 181 : 1713 9.
103. Chryssanthou E, Klingspor L, Tollemar J, Petrini B, Larsson L, Christensson B, et al. PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients. Mycoses 1999 42 : 239 47.
104. Meyers JD, Fluornoy N, Thomas E. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986 153 : 478 88.
105. Paulin T, Ringdén O, Lönnqvist B. Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation 1985 39 : 377 84.
106. Paulin T, Ringdén O, Nilsson B, Lönnqvist B, Gahrton G. Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation 1987 43 : 393 8.
107. Paulin T, Ringdén O, Lönnqvist B, Wahren B, Nilsson B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors. Scand J Infect Dis 1986 18 : 199 209.
108. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan N, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immunoglobulin. Ann Intern Med 1988 109 : 777 82.
109. Ringdén O, Lönnqvist B, Paulin T, Ahlmén J, Klintmalm G, Wahren B, et al. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrobial Chemother 1986 17 : 373 87.
110. Einsele H, Steidle M, Valbracht A, Saal J, Ehringer G, Müller C. Early occurrence of HCMV infection after BMT as demonstrated by the PCR technique. Blood 1991 77 : 1104 10.
111. Ljungman P, Loré K, Aschan J, Klaesson S, Lewensohn-Fuchs I, Lönnqvist B, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996 17 : 583 7.
112. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lönnqvist B, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998 66 : 1330 4.
113. Giralt S, Champlin R. Recurrence of the underlying malignant disease. In : Atkinson K editor. Clinical Bone Marrow Transplantation. Cambridge University Press, 1994 : 415 21.
114. Aschan J, Ringdén O, Sundberg B, Gahrton G, Ljungman P, Winiarski J. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991 7 : 113 9.
115. Ringdén O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P, et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991 7 : 221 6.
116. Thomas ED, Bryant JI, Buckner CD, Clift RA, Fefer A, Johnson FL, et al. Leukemic transformation of engrafted human marrow cells in vitro. Lancet 1972 1 : 1310 3.
117. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981 304 : 529 33.
118. Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996 18 : 921 9.
119. Ringdén O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996 24 : 71 9.
120. Ringdén O, Labopin M, Gorin NC, Schmitz N, Schaefer UW, Prentice HG, et al. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EMBT). Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol 2000 111 : 1130 7.
121. Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991 77 : 1423 8.
122. Carlens S, Aschan J, Remberger M, Dilber M, Ringdén O. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow Transplant 1999 24 : 629 35.
123. Kolb HJ, Mittermüller J, Clemm CH, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990 76 : 2462 5.
124. Kolb HJ, Schattenberg A, Goldman J, Hertenstein B, Jacobsen N, Arcese W, et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995 86 : 2041 50.
125. Carlens S, Remberger M, Aschan J, Ringdén O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 2001 7 : 31 8.
126. MacKinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-leukemia disease. Blood 1995 86 : 1261 8.
127. Dazzi F, Szydlo M, Craddock C, Cross NCP, Kaeda J, Chase A, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000 95 : 67 71.
128. Bishop MR, Tarantolo SR, Pavletic ZS, Lynch JC, Morris ME, Zacharias D, et al. Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol 2000 18 : 2269 72.
129. Potter MN, Cross NCP, van Dongen JJM, Saglio G, Oakhill A, Bartram CR, et al. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. Leukemia 1993 7 : 1302 14.
130. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringdén O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001 15 : 1976 85.
131. MacKinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994 83 : 3409 16.
132. Lawler M, Humphries P, McCann SR. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 1991 77 : 2504 14.
133. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringdén O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001 15 : 1976 85.
134. Morgan GJ, Hughes T, Janssen JW, Gow J, Guo AP, Goldman JM, et al. Polymerase chain reaction for detection of residual leukaemia. Lancet 1989 1 : 928 9.
135. Gabert J, Lafage M, Maranchini D, Thuret I, Carcassone Y, Mannoni P. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone marrow transplantation. Lancet 1989 2 : 1125 8.
136. Knechtli CJ, Goulden NJ, Hancock JP, Harris EL, Garland RJ, Jones CG, et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998 102 : 860 71.
137. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998 92 : 4072 9.
138. Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringdén O. The significance of graft-versus-host disease and pretransplant minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001 98 : 1982 4.
139. Noel DR, Witherspoon RP, Storb R, Atkinson K, Doney K, Mickelson EM, et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation of 56 long-term survivors. Blood 1978 51 : 1087 104.
140. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987 69 : 369 80.
141. Paulin T, Ringdén O, Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987 1 : 317 28.
142. Hirokawa M, Matsutani T, Horiuchi T, Kawabata Y, Kitabayashi A, Yoshioka T, et al. Extensive clonal expansion of T lymphocytes causes contracted diversity of complementarity-determining region 3 and skewed T cell receptor repertoires after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2001 27 : 607 14.
143. Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, et al. Assessment of thymic output in adults after hematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000 355 : 1875 81.
144. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+) CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002 99 : 3493 9.
145. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993 12 : 387 98.
146. Ringdén O, Witherspoon R, Storb R, Ekelund E, Thomas ED. B cell function in human marrow transplant recipients assessed by direct and indirect hemolysis-in-gel assays. J Immunol 1979 123 : 2729 34.
147. Omazic B, Hentschke P, Näsman-Björk I, Mattsson J, Oxelius V, Ringdén O, et al. Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic hematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens. Scand J Immunol 2005 61 : 72 81.
148. Storek J, Gillespy T 3rd., Lu H, Joseph A, Dawson MA, Gough M, et al. Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood 2003 101 : 4209 18.
149. Riddell SR, Greenberg PD. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev Med Virol 1997 7 : 181 92.
150. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995 345 : 9 13.
151. Gustafsson Å, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000 95 : 807 14.
152. Cavazzana-Calvo M, Fromont C, Le Deist F, et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990 50 : 1 7.
153. André-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002 360 : 130 7.
154. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005 106 : 1123 9.
155. Childs RW, Srinivasan R. In : Blume KG, Forman SJ, Appelbaum FR editors. Allogeneic hematopoietic cell transplantation for solid tumors. Thomas' Hematopoietic Cell Transplantation. Third Edition. Oxford, UK : Blackwell Publishing Ltd., 2004 : 1177 87.
156. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996 88 : 1501 8.
157. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998 16 : 986 93.
158. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett AJ. Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999 17 : 2044 9.
159. Zetterquist H, Hentschke P, Thörne A, Wernerson A, Mattsson J, Uzunel M, et al. A graft-versus-colonic cancer effect after allogeneic stem-cell transplantation. Bone Marrow Transplant 2001 28 : 1161 6.
160. Barkholt L, Bregni M, Remberger M, Peccatori J, Blaise D, Massenkiel G, et al. The European experience of allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma. Submitted.
161. Söderdahl G, Barkholt L, Hentschke P, Mattsson J, Uzunel M, Ericzon BG, et al. Liver transplantation followed by adjuvant nonmyeloablative hematopoietic stem cell transplantation for advanced primary liver cancer in humans. Transplantation 2003 75 : 1061 6.
162. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005 366 : 318 20.
163. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotypic transplants of bone marrow: analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968 6 : 230 47.
164. Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005 11 : 321 34.
165. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of human mesenchymal stem cells. Science 1999 284 : 143 7.
166. Haynesworth SE, Baber MA, Caplan AI. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992 13 : 69 80.
167. Le Blanc K, Tammik C, Götherström C, Zetterberg E, Ringdén O. HLA-expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003 31 : 890 6.
168. McIntosh K, Bartholomew A. Stromal cell modulation of the immune system. Graft 2000 3 : 324 8.
169. Le Blanc K, Tammik C, Sundberg B, Haynesworth S, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility system. Scand J Immunol 2003 57 : 11 20.
170. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003 75 : 389 97.
171. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005 305 : 33 41.
172. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003 76 : 1208 13.
173. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntos K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002 30 : 42 8.
174. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004 363 : 1439 41.
175. Horwitz EM, Prockop DJ, Gordon PL, Koo WWK, Fitzpatrick LA, Neel MD, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001 97 : 1227 31.
176. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002 99 : 8932 7.
177. Le Blanc K, Götherström C, Ringdén O, Hassan M, McMahon R, Horwitz E, et al. Fetal mesenchymal stem-cell engraftment in bone following in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005 79 : 1607 14.
178. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000 18 : 307 16.